Insmed’s Brinsupri, a DPP1 inhibitor for bronchiectasis, is poised as a blockbuster following FDA approval and positive clinical trials. The company confirmed plans for dual doses to provide doctors treatment flexibility and anticipates expanded access and payer coverage. This positions Brinsupri as a critical therapy addressing neutrophil-driven lung inflammation across a broad patient base.